Health Canada authorises Polivy (polatuzumab vedotin) for the first-line treatment of adults with large B-cell lymphoma

Roche

24 November 2022 - Authorization is based on pivotal data from the Phase 3 POLARIX trial, which met its primary outcome with a statistically significant improvement in progression-free survival in patients with previously untreated diffuse large B-cell lymphoma.

Roche Canada is pleased to announce that on 14 November 2022, Health Canada has authorised Polivy (polatuzumab vedotin for injection) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high grade B-cell lymphoma, Epstein-Barr virus positive diffuse large B-cell lymphoma not otherwise specified and T-cell/histiocyte rich large B-cell lymphoma.

Read Roche press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada